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Summary
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron
degenerative disease characterized by a progressive, and
ultimately fatal, muscle paralysis. The human VAMP-
Associated Protein B (hVAPB) is the causative gene of ALS type
8. Previous studies have shown that a loss-of-function mechanism
is responsible for VAPB-induced ALS. Recently, a novel mutation
in hVAPB (V234I) has been identified but its pathogenic potential
has not been assessed. We found that neuronal expression of the
V234I mutant allele in Drosophila (DVAP-V260I) induces defects
in synaptic structure and microtubule architecture that are
opposite to those associated with DVAP mutants and transgenic
expression of other ALS-linked alleles. Expression of DVAP-
V260I also induces aggregate formation, reduced viability, wing
postural defects, abnormal locomotion behavior, nuclear
abnormalities, neurodegeneration and upregulation of the heat-
shock-mediated stress response. Similar, albeit milder,
phenotypes are associated with the overexpression of the wild-
type protein. These data show that overexpressing the wild-type
DVAP is sufficient to induce the disease and thatDVAP-V260I is a
pathogenic allele with increased wild-type activity. We propose
that a combination of gain- and loss-of-function mechanisms is
responsible for VAPB-induced ALS.
 2013. Published by The Company of Biologists Ltd. This
is an Open Access article distributed under the terms of
the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution and reproduction in any
medium provided that the original work is properly
attributed.
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Introduction
Amyotrophic Lateral Sclerosis (ALS) is a progressive
neurodegenerative disorder characterized by the degeneration of
motor neurons leading to muscle atrophy, spasticity and,
eventually, death. ALS is traditionally classified into two
categories: familial ALS (FALS) and sporadic ALS (SALS)
(Pasinelli and Brown, 2006). Missense mutations (P56S and
T46I) at the N-terminal region of the human VAMP-associated
protein B gene (hVAPB) have been identified in both patients
with FALS and SALS (Nishimura et al., 2004; Funke et al., 2010;
Millecamps et al., 2010; Landers et al., 2008; Chen et al., 2010).
VAP proteins contain an N-terminal domain, which is highly
homologous to the nematode major sperm protein (MSP), a
central domain that forms a coiled-coil structure and a C-terminal
transmembrane domain (Nishimura et al., 1999; Kaiser et al.,
2005).
Members of the highly conserved VAP family have been
involved in a number of seemingly unrelated functions including
regulation of ER morphology, lipid transfer, vesicular trafficking
and dendritic morphogenesis (Soussan et al., 1999; Skehel et al.,
2000; Amarilio et al., 2005; Teuling et al., 2007; Lev et al., 2008;
Peretti et al., 2008; Kuijpers et al., 2013a). DVAP, the Drosophila
orthologue of hVAPB, controls synaptic structure, microtubule
cytoskeleton architecture and composition of post-synaptic
glutamate receptors (Pennetta et al., 2002; Chai et al., 2008). In
C. elegans and Drosophila, the MSP domain is cleaved, secreted
and acts as a ligand for Robo and Lar-like receptors to control
muscle mitochondria morphology, localization and function
(Tsuda et al., 2008; Han et al., 2012). Previous studies have
implicated ALS mutant alleles in an abnormal unfolded protein
response and in the disruption of the anterograde axonal transport
of mitochondria (Chen et al., 2010; Kanekura et al., 2006;
Langou et al., 2010; Suzuki et al., 2009; Gkogkas et al., 2008;
Mo´rotz et al., 2012). Transgenic expression in Drosophila of
either DVAP-P58S or DVAP-T48I, two ALS-linked alleles,
mirrors major hallmarks of the human disease including
neurodegeneration, aggregate formation, locomotion defects
and chaperone upregulation (Chai et al., 2008; Chen et al.,
2010). Several lines of evidence support the notion that P56S
mutation is a loss-of-function mutation, possibly via a dominant
negative effect. P56S mutant protein forms aggregates in which
the wild-type protein is recruited (Teuling et al., 2007). This
together with the analysis of mutant phenotypes associated with
transgenic expression of the P56S protein in several disease
models, confirms that P56S is a loss-of-function mutation











Ratnaparkhi et al., 2008; Tsuda et al., 2008; Suzuki et al., 2009;
Forrest et al., 2013; Kuijpers et al., 2013a). Furthermore, a
reduction in VAP protein levels has been reported in sporadic
ALS patients, SOD1 (Superoxide dismutase 1) mutant mice as
well as in induced pluripotent stem cells derived from ALS
patients (Anagnostou et al., 2010; Teuling et al., 2007; Mitne-
Neto et al., 2011). Recently, a novel mutation in the gene hVAPB
was identified in one ALS patient who has also a pathogenic
repeat expansion in C9ORF72 (chromosome 9 open reading
frame 72), another ALS causative gene. The mutation within the
hVAPB gene replaces the Valine at the position 234 of the highly
conserved transmembrane domain with an Isoleucine (V234I in
humans and V260I in Drosophila) (van Blitterswijk et al., 2012).
Moreover, no information is available about the dominant or
recessive inheritance of the mutation in humans and theoretical
predictions based on bioinformatics approaches give
contradictory results as to whether V234I mutation has a
damaging effect on the function of the protein (van Blitterswijk
et al., 2012; Ingre et al., 2013). To directly assess the pathogenic
effect of this mutation and to unveil potential new mechanisms of
disease pathogenesis, we carried out a series of functional studies
in a well-established Drosophila model of ALS.
Here we report that transgenic expression of DVAP-V260I
recapitulates major hallmarks of the human disease including
aggregate formation, reduced viability, neuromuscular defects,
abnormal locomotion behavior, neurodegeneration and
upregulation of the heat-shock-mediated stress response.
Moreover, we show that nuclear abnormalities represent a
novel aspect of ALS pathogenesis as expression of DVAP-
V260I either in neurons or muscles induces disruption in nuclear
architecture, position and shape. Surprisingly, we found that
transgenic expression of DVAP-V260I at the Drosophila larval
neuromuscular junction (NMJ) induces an increase in the number
of synaptic boutons and a decrease in their size. This phenotype is
highly reminiscent of the phenotype associated with the neuronal
overexpression of DVAP-WT protein and opposite to that of
DVAP loss-of-function mutations and transgenic expression of
the DVAP-P58S allele in neurons (Pennetta et al., 2002; Forrest
et al., 2013). In addition, overexpression of DVAP-WT protein
either in neurons or muscles induces phenotypes similar, albeit
milder, than those associated with V260I expression. Altogether
these data lead to the fundamental conclusion that DVAP-V260I
is a pathogenic allele with an increased wild-type activity and
that a combination of loss- and gain-of-function mechanisms are
responsible for VAP-induced ALS. In conclusion, on the basis of
the data reported here and those on previously identified
mutations, we propose that VAPB levels or/and activity must
be tightly regulated to keep neurons and muscles healthy as slight
disturbances in one direction or the other may induce cell
dysfunction and death.
Results
Presynaptic expression of either DVAP-V260I or DVAP-WT
transgenes leads to an overproduction of small synaptic
boutons
The V234I mutation in the hVAPB gene recently identified in one
ALS patient but not in a large number of healthy controls, is
located within the conserved and functionally important
transmembrane domain of VAP proteins (van Blitterswijk et al.,
2012) (supplementary material Fig. S1). Conversely, the
previously identified mutations, P56S and T46I, are localized
in a highly conserved stretch of amino acids within the MSP
domain (supplementary material Fig. S1C).
Presynaptic expression of the ALS-linked allele DVAP-P58S
induces a NMJ phenotype characterized by a decrease in the
number of boutons and an increase in their size (Chai et al., 2008;
Ratnaparkhi et al., 2008). These data prompted us to examine the
effect of DVAP-V260I expression on bouton formation and
synaptic structure. We generated several transgenic lines
expressing DVAP-V260I using the bipartite UAS/GAL4 system
and the panneural elav-Gal4 as a driver (Lin and Goodman,
1994). To examine basic synaptic morphology, NMJs were
stained with anti-HRP antibodies that label and allow for
visualization of the entire presynaptic membrane. Changes in
NMJ structure were assessed by counting the number of synaptic
boutons at muscles 12 and 13 of the abdominal segment A3. This
analysis revealed that transgenic expression of DVAP-V260I has
clear consequences on the expansion of boutons as compared to
controls. We were surprised to observe that, in this case, there is
an increase in the total number of synaptic boutons when
compared to controls (51463 in elav;DVAP-V260I versus 27262
in controls; P,0.001) (Fig. 1A,C). The size of boutons, however,
is dramatically reduced.
We have previously shown that an increase in the number of
boutons with a concomitant decrease in their size is associated
with the presynaptic overexpression of DVAP-WT protein and
that this phenotype is highly dependent on the dosage of the
DVAP (Pennetta et al., 2002). To further confirm and extend this
analysis, we generated a number of additional transgenic lines
expressing different levels of the DVAP-WT protein and found
that they all exhibited similar synaptic phenotypes. We selected a
weak line (DVAP-WT1) in which the number of boutons on the
muscles 12 and 13 of the segment A3 is 1.3-fold higher than in
controls and a strong DVAP-WT2 line that exhibits a 1.7-fold
increase in the number of synaptic boutons (Fig. 1A,C; P,0.001
in both cases).
We also noticed that in all transgenic lines the overall
morphology of the synapse has changed. In control NMJs,
synaptic boutons within a branch, resemble a string of beads with
boutons connected to one another by a short neuritic process
(Fig. 1B). In contrast, in larvae overexpressing either DVAP-
V260I or DVAP-WT transgenes, many small boutons appear to
bud off from a central bouton or from neuronal processes
connecting two boutons (Fig. 1B, arrows). Clusters of smaller
boutons surrounding central larger boutons are especially
common in DVAP-V260I overexpressors (Fig. 1B,D). Boutons
of similar size and morphology have been described in other
overgrowth synaptic phenotypes and they have been called
‘‘satellite’’ boutons (Torroja et al., 1999; Franco et al., 2004;
Kamimura et al., 2013). To correct for variations in total bouton
number, we quantified the amount of ‘‘satellite’’ boutons for each
genotype as a percentage of the mean total bouton number. We
found that presynaptic expression of DVAP-V260I using the
neuronal elav-Gal4 driver, induces a 2.6-fold increase in the
percentage of ‘‘satellite’’ boutons compared to controls
(Fig. 1B,D; P,0.001). Neuronal expression of either DVAP-
WT1 or DVAP-WT2 transgenes using the same Gal4 driver, leads
to 1.7-fold and 2.2-fold increase in satellite bouton number,
respectively (Fig. 1B,D; P,0.001 in both cases). In summary,
expression of either DVAP-WT or DVAP-V260I transgenes
induces a dramatic change on the overall morphology of the










synapse due, not only, to an increase in the total number of
boutons but also to an elevated number of ‘‘satellite’’ boutons.
It was surprising to find an overgrowth synaptic phenotype
associated with DVAP-V260I as transgenic expression of the
previously identified DVAP-P58S allele in neurons leads to an
opposite phenotype characterized by a decrease in the number of
boutons and an increase in their size (Pennetta et al., 2002; Chai
et al., 2008). The DVAP-P58S-induced phenotype is similar to
that associated with DVAP loss-of-function mutations (Pennetta
et al., 2002) leading to the hypothesis that DVAP-P58S is a loss-
of-function allele (Pennetta et al., 2002; Ratnaparkhi et al., 2008;
Chai et al., 2008). Accordingly, we found that in DVAP-P58S
transgenics the endogenous wild-type protein accumulates in the
aggregates distributed along the nerves and is depleted from its
normal synaptic localization (supplementary material Fig. S2E,
arrow). In particular, quantification of DVAP-positive staining at
NMJs of DVAP-P58S expressing neurons results in nearly 45%
decrease in the DVAP immunoreactivity compared to controls
(supplementary material Fig. S2A,E,F; P,0.001). We then
assessed the distribution and the local expression levels of
DVAP at NMJs of both the DVAP-V260I and the two DVAP-
WT lines. In agreement with the observed synaptic phenotypes,
we found that elav-Gal4-driven expression of every transgene
results in a rather homogenous distribution of DVAP at the
synapse and quantification of DVAP-positive immunoreactivity
revealed that in every case the amount of total protein is higher
than in controls (supplementary material Fig. S2). Specifically,
the increase in DVAP signal is 2.2-fold higher than in controls
for the DVAP-WT2 line while it is 1.7-fold and 1.8-fold over
the endogenous levels for DVAP-V260I and DVAP-WT1,
respectively (supplementary material Fig. S2, P,0.001 in all
cases). It is worth to note that although DVAP-WT1 and DVAP-
V260I lines express comparable amounts of their respective
transgenes, expression of the DVAP-WT1 transgene leads to
synaptic phenotypes and indeed to a number of other phenotypes
(see below) that are milder than those associated with the
transgenic expression of the mutant allele (compare
supplementary material Fig. S2 and Fig. 1). Furthermore,
phenotypes induced by the expression of DVAP-V260I in eight
tested lines are consistently more severe than those observed in a
comparable number of lines expressing the DVAP-WT transgene
(data not shown). Taken together, these results indicate that an
increase in the levels of DVAP wild-type protein is sufficient to
induce an overgrowth synaptic phenotype and that the DVAP-
V260I mutant allele acts as a hypermorphic allele as it has an
increased ability to promote bouton formation at the NMJ.
Presynaptic transgenic expression of DVAP-WT and DVAP-
V260I leads to bouton expansion by affecting microtubule
cytoskeleton architecture
Formation of synaptic boutons at axon terminals is achieved via
microtubules invading and promoting bouton budding from the
plasma membrane (Roos et al., 2000). Within the Drosophila
NMJ, excess of microtubule loop formation is associated with
overgrowth phenotypes, particularly those with an increased
number of ‘‘satellite’’ boutons (Franco et al., 2004; Kamimura
et al., 2013). Thus, we asked whether the increase in bouton
number in NMJs expressing either DVAP-WT or DVAP-V260I
transgenes is related to alterations in microtubule cytoskeleton
architecture. To address this question, we carried out
immunostainings against the Drosophila MAP1B homologue
Futsch, a marker of neuronal microtubule structures (Hummel
et al., 2000; Roos et al., 2000).
DVAP-WT1, DVAP-WT2 and DVAP-V260I transgenes were
each expressed in neurons using the elav-Gal4 driver and the
number of Futsch-positive microtubule loops was quantified for
every genotype. Presynaptic overexpression of DVAP-V260I
shows a drastic increase in the number of Futsch-positive loops as
Fig. 1. Synaptic boutons are smaller, more numerous and clustered at NMJs expressing either DVAP-V260I or DVAP-WT transgenes. (A) Representative
images of muscle 12 NMJs from abdominal segment 3 labeled with an antibody against HRP. Scale bars: 10 mm. (B) Illustration of the synaptic overgrowth
phenotype at HRP-stained NMJs of the indicated genotypes. In all panels arrows indicate satellite boutons. Scale bars: 10 mm. (C) Quantification of the total
number of boutons at muscles 12 and 13 of abdominal segment 3 and (D) quantification of satellite boutons at muscles 6/7 of the abdominal segment 3 for each
indicated genotype. elav-Gal4/+ NMJs were used as controls. Asterisks denote statistical significance compared to controls (***P,0.001).










compared to controls (3860.4% versus 1160.4% in controls,
P,0.001) (Fig. 2A,B,E). A significant increase in the proportion
of boutons containing a microtubule loop-like structure was also
observed following the presynaptic expression of DVAP-WT
transgenes (2660.5% for DVAP-WT1 and 3160.5% for DVAP-
WT2). However, in both cases, the change is less than that
associated withDVAP-V260I overexpressing mutants (Fig. 2C,D,E).
Of note, an increase in number of boutons with more
disorganized microtubule structure represented by splayed/
punctuate Futsch-positive immunostaining was reported in
larvae expressing DVAP-P58S and in DVAP loss-of-function
mutants (Pennetta et al., 2002; Forrest et al., 2013). As expected,
these NMJs exhibit an opposite synaptic phenotype characterized
by a decrease in number of boutons and an increase in their size
(Pennetta et al., 2002; Forrest et al., 2013). Thus, expression of
either DVAP-V260I or DVAP-WT transgenes in neurons, affects
the organization of microtubule architecture, albeit at a different
degree, with consequences on synaptic bouton formation and
division.
Targeted expression of either DVAP-V260I or DVAP-WT
transgenes induces aggregate formation and nuclear
abnormalities
DVAP is a ubiquitous protein and pathological alterations in
muscles during ALS have been considered to result from toxicity
of the mutant protein in motor neurons rather than a direct effect
of the pathogenic protein on striated muscles. In order to explore
whether the muscle is a direct target of DVAP-V260I and DVAP-
WT toxicity, the expression of either the wild-type or mutant
allele was selectively targeted to striated muscles, by using the
muscle-specific driver BG57-Gal4 (Budnik et al., 1996).
Abnormal aggregates containing disease proteins are a
common hallmark of several neurodegenerative disorders. We
therefore stained dissected NMJs with DVAP antibodies to assess
the localization of DVAP proteins in controls and in muscles
expressing either the DVAP-WT or the DVAP-V260I transgenes.
We found that while in controls DVAP is expressed throughout
the muscle, in DVAP-V260I muscles numerous and punctuate,
DVAP-immunopositive inclusions are present (Fig. 3A,B,
Fig. 5A,B, staining in red). Interestingly, similar inclusions
are also found in both the weak (DVAP-WT1) and strong
(DVAP-WT2) transgenic lines overexpressing the DVAP-WT
protein (Fig. 3C,D, Fig. 5C,D, staining in red). These data
indicate that overexpression of the DVAP-WT protein is
sufficient to induce the formation of aggregates and that
DVAP-V260I is a pathogenic allele.
Nuclear defects have been correlated with ageing as well as
with a number of pathological manifestations in humans
including Parkinson’s disease (Worman et al., 2010; Liu et al.,
2012). To determine whether nuclear architecture or/and
positioning are affected in our ALS fly model, we visualized
nuclei in muscles overexpressing either DVAP-V260I or DVAP-
WT transgenes using a nuclear marker and an anti-lamin
antibody. We found that in controls, nuclei are evenly spaced
along the muscle fibre while in muscles expressing either the
DVAP-V260I or the DVAP-WT transgenes, nuclei are closely
associated and exhibit a tendency to form clusters (Fig. 3). To
better evaluate the relative position of nuclei within a muscle, a
‘‘nearest-neighbor’’ analysis was conducted for each genotype
(see Materials and Methods for details). We found that, compared
to controls, the average shortest distance between nuclei is
severely reduced in muscles overexpressing the DVAP-V260I
transgene (P,0.001) while the overexpression of the DVAP-WT
transgenes has a significant but milder effect even in the case of
the strongest DVAP-WT2 line (Fig. 3E; P,0.01 for DVAP-WT1
and P,0.001 for DVAP-WT2).
We also noticed a drastic deterioration in nuclear architecture.
In particular, overexpression of either DVAP-WT or DVAP-V260I
transgenes results in deformed nuclei with an elongated structure.
To quantify this phenotype, we measured the width to length ratio
of nuclei within muscles per each genotype. As the nuclei in
control muscles have a distinct round shape, the width to length
ratio is close to 1. Any deviation from this value indicates a loss
of circularity and therefore a change in shape. We found that
nuclei within muscles overexpressing the DVAP-V260I transgene
are less round compared to nuclei in control muscles
(Fig. 3A,B,F; P,0.001) and a similar, albeit milder effect, was
observed in muscles overexpressing the DVAP-WT transgenes
(Fig. 3A,C,D,F; P,0.01 for DVAP-WT1 and P,0.001 for
DVAP-WT2). We also found that nuclei in muscles expressing
the DVAP-V260I transgene display a marked enlarged nuclear
volume compared to controls (Fig. 3G; P,0.001) as do the nuclei
Fig. 2. Expression of either DVAP-V260I or DVAP-WT transgenes in neurons affects synaptic microtubule cytoskeleton. (A) Representative images of
branches of NMJs of third instar elav-Gal4/+ control larvae, (B) elav;DVAP-V260I, (C) elav;DVAP-WT1 and (D) elav/DVAP-WT2 larval NMJs labeled with
antibodies against Futsch to show microtubule loops. Arrows in every panel indicate examples of Futsch loops. Scale bars: 10 mm. (E) Quantitative assessment of
Futsch-positive loops at A2 and A3 muscle 4 NMJs for each indicated genotype. The highest increase in the percentage of boutons exhibiting looped Futsch
staining (relative to the total number of boutons for each NMJ) was observed when DVAP-V260I was expressed presynaptically. Asterisks denote statistical
significance compared to controls (***P,0.001).










of muscles expressing the DVAP-WT transgenes, although to a
lesser extent (Fig. 3G; P,0.001 for the DVAP-WT1 and P,0.01
for DVAP-WT2). Intriguingly, a fraction of DVAP protein that is
predominantly a cytoplasmic protein was found to localize to the
nucleus in DVAP-V260I overexpressing muscles while in both
DVAP-WT lines this aberrant DVAP localization is nearly absent
Fig. 3. Postsynaptic expression of either DVAP-V260I or DVAP-WT transgenes results in aggregate formation and changes in nuclear shape, size and
positioning. (A) Third instar larval NMJs of BG57-Gal4/+ control, (B) BG57;DVAP-V260I, (C) BG57;DVAP-WT1 and (D) DVAP-WT2;BG57 NMJs expressing the
indicated transgene in muscles were labeled with antibodies specific for DVAP and lamin. Nuclei were visualized with the nuclear specific marker TO-PRO3.
(E) Quantification of the distance, (F) circularity and (G) volume of nuclei in randomly selected muscles for each indicated genotype. Sectioned volume renderings of
representative triple-labelled nuclei of BG57-Gal4/+ controls (H); (I) BG57;DVAP-V260I; (J) BG57;DVAP-WT1 and DVAP-WT2;BG57 (K). Scale bars: 10 mm.
Asterisks denote statistical significance. ***P,0.001, **P,0.01.










(Fig. 3H–K). A nuclear localization for DVAP has never been
described before but previous studies have shown that
translocation from the cytoplasm to the nucleus of a-synuclein
associates with increased toxicity and neurodegeneration in
Parkinson’s disease (Kontopoulos et al., 2006). Moreover, an
increased number of small and condensed pyknotic nuclei was
predominantly observed in muscles overexpressing the DVAP-
V260I transgene while such nuclei are significantly less in the
weak DVAP-WT1 line (Fig. 3, white arrows).
Finally, we noticed that larger and malformed nuclei are also
observed in neurons of larval brains expressing either the DVAP-
WT or DVAP-V260I transgenes and again the phenotype appears
to be more severe when the mutant transgene is expressed
(Fig. 4). In addition, expression of DVAP-V260I in neurons also
induces accumulation of prominent inclusions that appear to be
very large and intensely immunoreactive to DVAP antibodies
(Fig. 4A,B). In contrast, in neurons of the weakest DVAP line
(DVAP-WT1), small and isolated foci accumulating DVAP were
observed. Although not directly quantified, the number of these
foci appear to be increased in neurons of the strongest DVAP-
WT2 line (Fig. 4C,D). Interestingly, no small pyknotic nuclei
were observed in these neurons that present an aberrant nuclear
architecture.
Taken together, these data demonstrate that transgenic
expression of either DVAP-V260I or DVAP-WT in neurons as
well as in muscles elicits the formation of aggregates and a severe
disruption in the architecture, size and positioning of nuclei.
Induction of the heat-shock response in DVAP-WT and DVAP-
V260I overexpressors
In many neurodegenerative diseases including ALS, aggregates
are thought to be formed from the accumulation of misfolded
proteins that trigger the upregulation of chaperone proteins
(Vabulas et al., 2010). We assessed whether this was also the case
for larvae expressing either DVAP-V260I or DVAP-WT
transgenes in their muscles. In controls, Hsp70 is barely
detectable and results in faint and diffuse staining throughout
the cytoplasm (Fig. 5A). In transgenic animals expressing the
DVAP-V260I construct specifically in the striated muscles, there
is an increase in the expression levels of Hsp70 that appears to
concentrate in puncta mainly localized inside the nucleus
(Fig. 5B). In transgenic muscles expressing the DVAP-WT
transgenes, an increase in the accumulation of puncta
immunoreactive to the Hsp70 was observed. These puncta are
partially localized into the nucleus in muscles expressing the
strongest wild-type transgene DVAP-WT2 (Fig. 5D). Conversely,
in muscles expressing the weak DVAP-WT1 transgene, puncta
are still present in the cytoplasm, although the majority of them
preferentially accumulate in the perinuclear region (Fig. 5C). The
phenomenon of the Hsp70 relocating from the cytoplasm to the
nucleus during a stress response is poorly understood; however, it
is clear that this relocation is directly linked and is part of the
cellular response to stress (Vabulas et al., 2010). Taken together,
these data indicate that in DVAP-V260I as well as in DVAP-WT
overexpressors, a stress response mediated by heat-shock proteins
Fig. 4. Expression of DVAP-V260I and DVAP-
WT transgenes in neurons leads to aggregate
accumulation and disruption of nuclear
architecture. (A) Brains of elav-Gal4/+ control
larvae and (B) elav;DVAP-V260I, (C) elav;
DVAP-WT1, (D) elav/DVAP-WT2 larval brains
expressing their respective transgene in neurons
were immunostained with antibodies specific for
DVAP and Lamin. Nuclei were labeled with the
nuclear marker TO-PRO3. Scale bars: 10 mm.










has been induced and that the intensity of this response directly
correlates with the toxicity of the overexpressed protein.
Expression of DVAP-V260I and DVAP-WT in adult flies induces
reduced viability, compromised locomotion behavior and
neuromuscular defects
We showed that expression of DVAP-V260I and DVAP-WT
transgenes in larval neurons and muscles causes a number of
phenotypes closely mirroring the human pathology. We then
sought to test whether the same transgenes have any effect on the
adult neuromuscular junctions. We first expressed the DVAP-
V260I or the DVAP-WT transgenes in the adult nervous system by
using the panneural driver elav-Gal4. Flies expressing either the
DVAP-V260I transgene or any of the two wild-type transgenic
construct, are able to pupate and adults eclose from pupae.
However, the rate of eclosion is different depending on the
overexpressed transgene (Fig. 6A). Flies expressing the DVAP-
WT1 transgene have a small but statistically significant decrease
in the rate of eclosion (Fig. 6A; P,0.05) while for flies
expressing the strongest wild-type allele, DVAP-WT2, the rate
of eclosion is 75% (Fig. 6A; P,0.001). A strong reduction in the
number of flies eclosed as viable adults is observed when the
expression of the DVAP-V260I was targeted in the adult neurons.
In this case only 35% of pupae eclose to give an adult fly
(Fig. 6A). However, all flies, irrespective of their genotypes,
display distinctive postural and locomotion defects as viable
adults. While in controls, wings run dorsal and parallel to the
body, surviving mutants exhibit different wing posture
phenotypes including droopy and held-up wings (Fig. 6B–D).
Additionally, surviving adult flies are severely uncoordinated and
within a few days following eclosion, get stuck to the food and
die. When the expression of either DVAP-WT or DVAP-V260I
constructs is targeted to all muscles by using the MHC-Gal4
driver, the progeny exhibits the same wing posture phenotypes as
for the neuronal expression of the same transgenes but their
eclosion ratio is similar for every transgene and closer to that of
controls (supplementary material Fig. S3). Similar adult phenotypes
have been described in a number of fly models of human
neurodegenerative diseases including Fragile X syndrome and
Parkinson’s disease and have been attributed to neuromuscular
dysfunction (Zhang et al., 2001; Clark et al., 2006).
Targeted expression of either DVAP-WT or DVAP-V260I
transgenes in the adult Drosophila eye causes neuronal
degeneration
Neuronal degeneration in Drosophila models of human
neurodegenerative disorders including ALS is usually assessed
in the adult fly eye. To determine whether overexpression of
DVAP-WT protein and transgenic expression of DVAP-V260I
causes neurodegeneration, we used the ey-Gal4 driver to
specifically target the expression of these transgenes in the
adult fly eye (Halder et al., 1998; Hauck et al., 1999). Adult fly
eyes expressing either DVAP-WT or DVAP-V260I transgenes
display a range of structural abnormalities. As compared with
Fig. 5. Upregulation and subcellular
relocalization of Hsp70 in striated muscles
overexpressing either DVAP-V260I or DVAP-
WT constructs. (A) NMJs of BG57-Gal4/+
control larvae and (B) BG57;DVAP-V260I,
(C) BG57;DVAP-WT1 and (D) DVAP-WT2;BG57
larvae expressing their respective transgene were
immunolabeled with antibodies specific for
DVAP and Hsp70 while nuclei were visualized
with the TO-PRO3 nuclear marker. Scale bars:
10 mm. See text for comments.










controls, eyes expressing either the DVAP-WT or DVAP-V260I
transgenes are reduced in size and show a marked roughness over
the entire surface (Fig. 7A). A striking aspect of the eye
phenotype induced by the overexpression of either DVAP-WT
or the DVAP-V260I transgenes, is the high degree of
heterogeneity in the severity of the phenotype within the same
line and even within the same fly as, in many cases, one of the
eyes exhibits a more extensive degeneration than the eye on the
opposite side. We therefore quantified the phenotype in both
control and overexpressor lines by measuring the eye size in a
comparable number of flies for every genotype. Overall, the eye
size of DVAP-V260I transgenic flies is less than 50% of the
control size while the measured reduction in eye size for DVAP-
WT1 and DVAP-WT2 was 30% and 20%, respectively (Fig. 7C;
P,0.001 in all cases).
Histopathological analysis of paraffin embedded sections of
transgenic eyes expressing either DVAP-WT or DVAP-V260I
confirmed the degeneration of cells beneath the external surface
of the eye (Fig. 7B). In particular, photoreceptor morphology is
disrupted and several vacuoles are visible. Vacuolization has
Fig. 6. DVAP-V260I and DVAP-WT overexpressors
display reduced viability and wing postural defects.
(A) Eclosion rate of flies of the designated genotype.
(B) elav-Gal4/+ control flies with a dorsal wing posture.
(C) Held-up wings and (D) droopy wing flies. See text for
comments. Asterisks denote statistical significance.
***P,0.001, *P,0.05.
Fig. 7. Expression of either DVAP-V260I or DVAP-WT transgenes in adult Drosophila eyes induce neurodegeneration. (A) Stereomicroscope images of
ey-Gal4/+ control eyes and eyes of the indicated genotypes. (B) Frontal sections of control and transgenic eyes of the indicated genotypes stained with H&E.
White arrows point to vacuoles in photoreceptors while the black arrowheads indicate areas of extensive tissue degeneration. (C) Quantification of the eye surface
area of every genotype. Scale bars: 50 mm. Asterisks denote statistical significance (***P,0.001).










been observed in a number of fly models of neurodegenerative
diseases and the appearance of vacuoles has been correlated to
neurodegeneration (Chan and Bonini, 2000). Of note, the
strongest phenotype for both the reduction in the eye size and
the degeneration of the internal eye is that associated with the
expression of the DVAP-V260I transgene (Fig. 7). The internal
tissues of transgenic eyes expressing the DVAP-WT protein are
disrupted in a similar way, albeit to a lesser extent, especially
when the weakest line DVAP-WT1 is considered (Fig. 7B). In
conclusion, these data indicate that increasing the level of
expression of the DVAP-WT protein is sufficient to trigger
neurodegeneration, although transgenic expression of the mutant
DVAP-V260I allele appears to be more efficient in inducing
neuronal cell death.
Discussion
Recently, a novel mutation in the gene hVAPB has been
identified in one ALS patient who is also known to have a
pathogenic repeat expansion in the C9ORF72 gene. The missense
mutation replaces the Valine with an Isoleucine at codon 234, a
highly conserved residue within the C-terminal transmembrane
domain of VAP proteins (van Blitterswijk et al., 2012). In
Drosophila, the transmembrane domain of DVAP binds the
phosphoinositide phosphatase Sac1 to control phosphoinositide
levels whose upregulation is responsible for neurodegeneration
and a number of synaptic phenotypes including altered synaptic
morphology and mislocalization of several post-synaptic markers
(Forrest et al., 2013). Moreover, in mammals the transmembrane-
mediated interaction of VAPB with the ER–Golgi recycling
protein YIF1A controls dendritic remodeling in the central
nervous system (Kuijpers et al., 2013a). It is therefore plausible
that mutations targeting this important functional domain may
have a pathogenic effect.
Here we report that transgenic expression of DVAP-V260I in
Drosophila, induces mutant phenotypes that closely mirror major
hallmarks of ALS such as structural remodeling at NMJs,
formation of aggregates, abnormal locomotion behavior, reduced
viability, neuromuscular defects and upregulation of the heat-
shock-mediated stress response. In addition, muscles and neurons
expressing the DVAP-V260I transgene exhibit striking
abnormalities in nuclear positioning, shape and size.
Interestingly, nuclear abnormalities have never been linked to
ALS pathogenesis.
Previously identified disease mutations in hVAPB are loss-of-
function mutations, possibly by a dominant negative mechanism
(Ratnaparkhi et al., 2008; Forrest et al., 2013; Kuijpers et al.,
2013a). We were therefore surprised to find that transgenic
expression of DVAP-V260I construct consistently produces
similar but more severe phenotypes than those associated with
the overexpression of the wild-type protein. Collectively, our
results show that a gain-of-function mechanism is responsible for
VAPB-induced ALS and that the V234I is a pathogenic allele
with an increased wild-type activity. In conclusion, we propose
that both gain- and loss-of-function effects play an important role
in driving the damage, which ultimately leads to cellular
downfall and clinical expression of the disease.
Nuclear abnormalities in ALS pathogenesis
Mispositioning of nuclei has been associated with decreased cell
survival in vertebrate central nervous system (Tsujikawa et al.,
2007). In striated muscles, myonuclei appear as rounded
structures evenly spaced along muscle fibers separated from the
bulk of the cytoplasm, which contains densely arranged
myofibrils. The mechanisms establishing and maintaining this
highly ordered distribution of nuclei and its relevance to muscle
function is not known but several human myopathies are caused
by mutations in genes such as Nesprins that control the correct
position and distribution of nuclei in muscles (Puckelwartz et al.,
2010). Furthermore, Nesprin-1 knockout mice exhibit 50%
lethality and those surviving display progressive muscle
wasting and abnormal gait (Puckelwartz et al., 2009). Nuclear
architecture defects have been shown to correlate with aging as
well as with a number of human diseases, including Parkinson’s
disease (Liu et al., 2012).
To study the role that nuclear position and structure might have
in ALS, we targeted the expression of DVAP-WT and DVAP-
V260I in neurons and muscles. Our morphometric analysis
revealed that overexpression of the DVAP-V260I results in
deformed nuclei with an elongated structure and a marked
enlarged nuclear volume. We also found that in DVAP-V260I
transgenic muscles the average distance between nuclei is
remarkably reduced and sometimes, nuclei are found to
aggregate into clusters. A similar deterioration in nuclear
architecture and positioning was observed in muscles
overexpressing DVAP-WT transgenes but, overall, the defects
are milder than those associated with the expression of DVAP-
V260I even when the strongest DVAP-WT2 transgene is
expressed. In summary, nuclear abnormalities are more
prominent in transgenic conditions associated with a more
aggressive disease phenotype.
Finally, small and condensed pyknotic nuclei were observed in
muscles expressing DVAP-V260I and to a lesser extent in those
overexpressing the DVAP-WT transgene. Although the presence
of pyknotic nuclei is a hallmark of apoptosis, we do not believe
that the observed nuclear abnormalities are a mere consequence
of apoptotic cell death. No condensed, pyknotic nuclei are
present in neurons expressing any DVAP-WT transgenes or
DVAP-V260I protein at the time when nuclear abnormalities are
already visible. These results suggest that defects in nuclear
architecture and distribution may precede the appearance of
apoptotic hallmarks. Indeed recent studies suggest that alterations
in nuclear structure and positioning represent an irreversible
trigger of apoptosis rather than a consequence of this process (Liu
et al., 2012).
Taken together, these studies identify the nucleus as a novel
cellular organelle involved in ALS pathogenesis and open new
avenues for the potential development of therapies targeting this
fundamental cellular structure.
Expression of either DVAP-V260I or DVAP-WT transgenes
recapitulates major ALS-related hallmarks
The data discussed in the previous paragraph suggest that our
DVAP-V260I fly model may function as a platform for the
discovery and study of novel and, at the moment, elusive aspects
of ALS pathogenesis. Our data also suggest that this model
recapitulates many of the phenotypes known to be associated
with ALS and indeed with a number of other neurodegenerative
diseases.
In Drosophila, DVAP interacts with the adhesion molecule
Dscam to affect synaptic connectivity and its homologue in
mammals, VAPB, is required for intracellular membrane
trafficking and normal dendritic growth (Yang et al., 2012;










Kuijpers et al., 2013a). In addition, loss-of-function mutations in
the SMN (Survival motor neuron) gene, the causative gene of the
motor neurone disease spinal muscular atrophy (SMA), induces
defects in axons and synaptic structure (Torres-Benito et al.,
2012). Similar results have been reported for the ALS-linked
gene VCP (Valosin Containing Protein) as mutations in this gene
lead to impaired synaptogenesis and spinogenesis (Wang et al.,
2011). To study the effect of DVAP-WT and mutant DVAP-V260I
transgenes on synaptic remodeling and structure, we focused on
the Drosophila larval NMJ. Morphological analysis shows that at
NMJs overexpressing either DVAP-WT or DVAP-V260I
transgenes, boutons are smaller, more numerous and tend to
form dense clusters especially at the ends of terminal branches.
Overgrowth synaptic phenotypes have been associated with
alterations in microtubule networks and specifically with an
increase in the percentage of boutons containing microtubule
loop-like structures (Torroja et al., 1999). Indeed we found that at
NMJs expressing DVAP-V260I there is a specific increase in this
category of boutons. Similar, but less severe, phenotypes are
associated with the transgenic expression of the DVAP-WT
protein. In contrast, expression of the ALS-linked allele DVAP-
P58S in neurons and loss-of-function mutations in DVAP induce
a reduction in number of boutons and an increase in their size. A
shift in microtubule structures towards less organized
morphologies, which is often associated with undergrowth
synaptic phenotypes, was also observed in this transgenic
condition (Pennetta et al., 2002). In agreement with these data,
we show that there is a local increase in DVAP levels at DVAP-
V260I expressing NMJs and a decrease in synapses expressing
DVAP-P58S. In summary, we propose that disruption of synaptic
remodeling and structure may represent a fundamental and
common aspect of disease pathogenesis in ALS and that the
DVAP-V260I allele, in contrast to the DVAP-P58S allele, exhibits
an increased wild-type activity.
A common feature of neurodegenerative diseases is the
presence of misfolded protein aggregates in affected regions of
the nervous system. Many neurodegenerative proteins behave
like prion proteins (Polymenidou and Cleveland, 2012). In vivo
and in vitro studies have shown that these proteins exhibit a high
tendency to self-aggregate because of their intrinsic ability to
undergo a series of kinetically unfavorable conformational
changes to produce misfolded proteins. Increasing the
concentration of the native protein favors the formation of
aggregates and disease-linked mutations often appear to confer to
the protein an increased ability to generate inclusions (Eisele,
2013). Further studies are necessary to assess whether DVAP is a
prion-like protein. However, as expected for a prion-like protein,
DVAP-WT overexpression is sufficient to induce the formation
of aggregates in a dosage-dependent manner and transgenic
expression of the mutant DVAP-V260I protein effectively leads
to the accumulation of large protein inclusions even at relatively
low doses.
In our Drosophila model, muscles expressing the DVAP-V260I
transgene, which associates with the most aggressive disease
phenotype, exhibit a relocalization of DVAP protein into the
nucleus. DVAP remains predominantly localized to the
cytoplasm in controls and in all the other transgenic conditions
exhibiting a milder disease phenotype. The mechanism by which
DVAP enters the nucleus is unclear; however, this relocalization
closely resembles the relocalization from the cytoplasm to the
nucleus reported for a-synuclein, a protein involved in
Parkinson’s disease (PD). Normal and PD-linked a-synucleins
promote toxicity by relocating to the nucleus where they bind to
histones and inhibit their acetylation. Administration of histone
deacetylase (HDAC) inhibitors restores the histone acetylation
state and rescues a-synuclein-mediated toxicity (Kontopoulos
et al., 2006). Remarkably, administration of HDAC inhibitors to
ALS mouse models successfully decreases cell toxicity (Yoo and
Ko, 2011).
Implications for ALS pathogenesis
Loss or depletion of VAPB activity in zebrafish, worms and mice
induce a relatively mild phenotype possibly because of a
functional redundancy between closely related VAP proteins in
these models (Kabashi et al., 2013; Han et al., 2012). In
Drosophila, only one VAP gene is present and therefore its
inactivation leads to the appearance of a more aggressive mutant
phenotype (Pennetta et al., 2002; Forrest et al., 2013). Mice
expressing the VAPB-P56S transgene have been generated and
they exhibit no overt neurodegenerative phenotype (Aliaga et al.,
2013; Qiu et al., 2013; Tudor et al., 2010; Kuijpers et al., 2013b).
However, a recent report describes degeneration of a subset of
motor neurons in mice expressing higher levels of the VAPB-
P56S transgene (Aliaga et al., 2013). In addition,
neurodegeneration has been associated with the expression of
the same transgene in cell culture systems (Langou et al., 2010;
Suzuki and Matsuoka, 2011; Teuling et al., 2007). Taken together
these considerations further underscore the importance of VAPB
dosage in inducing ALS-like phenotypes, including
neurodegeneration. It is not uncommon that genetic models fail
to reproduce the full range of clinical manifestations associated
with a human disease and for this non-human primate models
should represent a better option. Genetic models, however,
remain invaluable tools to dissect mechanistic aspects of disease
pathogenesis.
Studies in several model systems showed that the P56S
mutation induces ALS by a loss-of-function mechanism, possibly
due to a dominant negative effect (Ratnaparkhi et al., 2008;
Tsuda et al., 2008; Suzuki et al., 2009; Forrest et al., 2013;
Kuijpers et al., 2013a). Furthermore, a reduction in VAP protein
levels have been reported in sporadic ALS patients, SOD1 mutant
mice as well as in induced pluripotent stem cells derived from
ALS patients (Teuling et al., 2007; Anagnostou et al., 2010;
Mitne-Neto et al., 2011). The dominant negative effect of P56S
mutation is further supported by the observation that the mutant
protein accumulates into intracellular inclusions, which also
sequester the wild-type protein (Teuling et al., 2007; Chen et al.,
2010). Here we uncover a novel mechanism for the disease
pathogenesis and we show that increasing the levels and/or
activity of DVAP may be detrimental as well. The notion that
increased hVAPB levels are sufficient to induce
neurodegeneration would be greatly supported by finding that
duplications or mutations in the non-coding regions of the
hVAPB gene are associated with ALS in humans. For hVAPB,
however, such mutations have yet to be identified. These and
other studies indicate that, in many cases, a strict dichotomy
between loss-of-function versus gain-of-function mechanisms do
not respond to a biological reality as both mechanisms seem to be
at play (Robberecht and Philips, 2013). In support of this
hypothesis, variations in the dosage of the SMN gene have been
shown to induce two closely related motor neuron diseases as
loss-of-function mutations in SMN cause Spinal Muscular










Atrophy while duplications of the same gene have been linked to
ALS (Bu¨rglen et al., 1995; Blauw et al., 2012).
Finally, our data are compatible with a model in which, in
DVAP-V260I-induced ALS, gain- and loss-of-function
mechanisms may coexist within the same neuron depending on
the subcellular compartment. At the presynaptic compartment, a
local increase in DVAP levels induces a remodeling of synaptic
morphology and microtubule architecture compatible with a
gain-of-function mechanism. Conversely, in neuronal cell bodies
the inherent ability of wild-type hVAPB to be included into
aggregates that may also function as a sink for other important
proteins, suggests that DVAP could be pathogenic by a possible
loss-of-function mechanism. The complexity of such a scenario
pinpoints to novel opportunities for possible therapies but at the
same time makes the task of finding an effective therapeutic
strategy particularly challenging.
Materials and Methods
Fly strains and husbandry
Flies were reared in standard cornmeal–molasses medium and maintained at room
temperature unless otherwise specified. To drive the expression of DVAP
transgenes in neurons, larval muscles and adult eyes we used the elav-Gal4 line
(Lin and Goodman, 1994), the BG57-Gal4 line (Budnik et al., 1996) and the ey-
Gal4 line (Halder et al., 1998; Hauck et al., 1999), respectively. We used the ey-
Gal4 instead of the GMR-Gal4 driver because GMR-GAL4 has been shown to
induce eye neurodegeneration on its own (Reza´val et al., 2007). Transgenic
expression in adult muscles was achieved by using the MHC-Gal4 line.
Generation of DVAP-WT and DVAP-V260I transgenic lines
Site-directed mutagenesis on DVAP cDNA was performed using the Quick
Change Site Directed Mutagenesis Kit (Agilent, Colorado Springs, CO, USA)
following manufacturer’s instructions. Gal4-resposive transgenic lines were
constructed cloning DVAP-WT and DVAP-V260I cDNAs in the pUAST vector
(Brand and Perrimon, 1993) using the cloning strategy previously described
(Pennetta et al., 2002). Constructs were injected into embryonic germ cells and
transgenic lines were established following standard procedures (Genetic Services,
Inc., Sudbury, MA, USA). Given the strong dosage-dependent effect on mutant
phenotypes observed for both the DVAP-WT and V260I transgenes, in generating
the transgenic lines we opted for the method of random transgene insertion instead
of that in which transgenes are inserted at specific sites (Bischof et al., 2007).
Using this approach, we generated 8 independent transgenic lines expressing
different levels of either DVAP-WT or DVAP-V260I proteins.
Genetics
For temperature pulses, to induce a higher expression of the Gal4 protein, flies of
the relevant genotypes were left to mate at room temperature for 20–24 hours and
then the parents were removed while the progeny was shifted to 30 C˚ in a water
bath. Only for the ey-GAL4 experiments, crosses and rearing of animals were
performed at 25 C˚ because at higher temperatures adult flies fail to eclose, possibly
due to an ectopic, toxic expression of the transgene in areas of the nervous system
other than the eye.
Immunohistochemistry
To study NMJ morphology, wandering third instar larvae were dissected and
processed as previously described (Pennetta et al., 2002). Control genotypes used
for analysis were F1 larvae from Canton-S males crossed to the homozygous
females of the relevant GAL4 driver line. Primary antibodies are rabbit anti-HRP
antibodies (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA,
USA), mouse anti-Futsch 22C10 monoclonal antibody (1:200, Developmental
Studies Hybridoma Bank, Iowa City, IA, USA), rabbit anti-Lamin antibody (1:
500), guinea pig anti-DVAP antibody (1:500, Pennetta et al., 2002) and mouse
anti-Hsp70 (1:200, Affinity Bioreagents, Rockford, IL, USA). Secondary
antibodies were used at a 1:200 dilution.
Confocal analysis and imaging
Confocal z-stacks were acquired on a Nikon A1R (Nikon, Kingston upon Thames,
Surrey, UK) using an660/1.4 NA oil immersion plan-apochromat with a sampling
rate of 0.460.460.27 mm in x, y and z, respectively. For multicolour images a
channel series protocol was used to minimize bleed through. The same confocal
gain settings were applied to control and transgenic samples. Images were
processed using Imaris v 7.3.0 (Bitplane, Zurich, Switzerland). For z-stacks, iso-
surfaces were created in surpass mode for both lamin and TO-PRO3; whole nuclei
were selected from the 3D image volume and measurements for volume, and
object bounding box size were acquired. Imaris measurement-pro was used to
measure the distances between nuclei along each muscle fibre. To measure the
circularity of nuclei within muscles, images were analyzed with ImageJ software
(ImageJ software, National Institute of Health, Bethesda, MD, USA). Circularity is
defined as 4p6Area/Perimeter2, where 1 represents a perfect circle and 0 an
infinitely elongated polygon. For visualization of DVAP within the nucleus a 3D-
volume view of DVAP and TO-PRO3 was combined with an iso-surface of the
lamin and a contour plane was used to cut into the lamin volume and show the
localization of DVAP within the nucleus.
NMJ morphological analysis
To quantify the overgrowth phenotypes at the NMJ, body wall muscle
preparations were labeled with the presynaptic marker anti-HRP and two
different parameters were measured. The total number of synaptic boutons was
counted at muscles 12 and 13 of abdominal segment A3 and the percentage of
satellite boutons (satellite6100/total boutons) on muscles 6 and 7 of the
abdominal segment A3 was also determined. Satellite boutons at the NMJs were
defined, identified and quantified according to Torroja et al. (Torroja et al.,
1999). The number of loop containing boutons was counted on muscles 4 of the
abdominal segments A2 and A3 and expressed as a percentage of the total
number of boutons for each NMJ.
Quantification of the distance between myonuclei
A nearest-neighbor analysis was performed to quantify the distance between nuclei
along a given myofibre. A nearest-neighbor analysis determines the average
distance between a nucleus and its single closest neighbor within a muscle. To
identify the closest neighbor for each nucleus within a muscle, the distance
between the center of a nucleus and the center of each closely surrounding nucleus
was measured. Only the shortest distance between a nucleus and its nearest
neighbor was recorded per each nucleus within a muscle and the average of these
distances was taken as a measure of the shortest distance between nuclei in a given
muscle.
Statistical analysis
Statistical analysis including graphing was performed using GraphPad 5.0
(GraphPad Software Inc, LaJolla, CA, USA). For all the experiments, a one-way
ANOVA test was applied to the samples. Tukey’s multiple comparison tests were
used as a post-hoc test when a significant difference was found in the ANOVA test.
Data throughout the paper are presented as mean6 s.e.m. A minimum of 10 larvae
were analyzed per every genotype. At least 20 flies per genotype were analyzed in
scoring the adult eye phenotype.
Analysis and quantification of the Drosophila adult eye phenotype
For the eye morphology, two-dimensional images were obtained using a Nikon
D5100 DSLR camera attached to a SZX9 Nikon stereomicroscope (Nikon,
Kingston upon Thames, Surrey, UK). To quantify the eye surface area images were
analyzed with ImageJ software. For histology, flies were raised at 25 C˚ and
collected immediately after eclosion. Heads were severed and place in fresh
fixative (ethanol:formaldehyde:acetic acid at 85:10:5) overnight at 4 C˚. Heads
were then washed and placed in 70% ethanol and processed into paraffin using
standard histological procedures. 10 mm serial sections were obtained and
rehydrated with PBS. Sections were stained with H&E.
Adult phenotypes
Eclosion rates were determined by counting numbers of empty versus full (dead)
pupae on the sides of vials in which flies of different genotypes had been allowed
to lay for comparable time periods. Food was covered with a thick layer of yeast
powder to avoid that eclosed flies with an aberrant wing posture would get stuck to
the food. Flies exhibiting an aberrant posture in their wings were collected and
their phenotype was recorded using an Olympus ZEX stereomicroscope (Olympus,
Hamburg, Germany) equipped with a Nikon D5100 DSLR camera.
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Fig. S1. Identification of the V234I/V260I mutation on VAP proteins. (A) Predicted functional domains in hVAPB: a transmembrane domain (blue) at the
C-terminus, a coil-coiled domain (brown) in the middle and a domain (green) at the N-terminus showing a significant homology to the nematode major sperm protein
(MSP). The Val234 residue (indicated by an arrow) is located within the transmembrane domain and it has been replaced by an Isoleucine. (B) High degree of
conservation of the transmembrane domain in VAP proteins from different species. (C) Sequences of human VAPB (hVAPB) protein and its Drosophila orthologue
DVAP were aligned by using the ClustalW version 1.82 alignment program available from EMBL–EBI. Asterisk indicates an identity match; colon indicates
conservation between amino acids with strongly similar properties (scoring .0.5 in the Gonnet PAM 250 matrix) and period indicates a conserved substitution
between amino acids with weakly similar properties (#0.5 in the Gonnet PAM 250 matrix). Red boxes highlight the amino acid residues changed by the ALS8
causing mutations identified so far. The Drosophila protein (DVAP) exhibits the same functional domains as the hVAPB.
Fig. S2. Synaptic levels of DVAP in different genetic contexts. (A) Control elav/+ NMJs and (B) elav;DVAP-V260I, (C) elav;DVAP-WT1, (D) elav/DVAP-WT2,
(E) elav;DVAP-P58S NMJs stained with antibodies specific for DVAP and for anti-HRP. Scale bars: 10 mm. (F) Quantification of synaptic DVAP intensity for
the reported genotypes. DVAP fluorescence intensity is presented as a relative ratio of fluorescence intensity values of DVAP against those of controls. Note that in
DVAP-P58S transgenic line aggregates are evident in the terminal part of the nerve (arrow in panel E) and the endogenous protein at the synapse has decreased
to about 6664% of the control value. Conversely, compared to controls DVAP levels at the synapse are significantly increased in all the other transgenic lines
(P,0.001 in all cases). However, upregulation of DVAP levels in neurons expressing DVAP-V260I is comparable to that induced by the DVAP-WT1 transgene
(P.0.05) and significantly lower than that associated with the strongest DVAP-WT overexpressing line DVAP-WT2 (P,0.001). The difference in DVAP levels
between DVAP-WT1 and DVAP-WT2 lines was statistically significant (P,0.001).










Fig. S3. Overexpression of DVAP-WT and transgenic expression of DVAP-
V260I in muscles does not affect viability. Eclosion rate of flies of the
indicated genotypes. MHC-Gal4/+ flies were used as controls. P.0.05.
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